(Q39505317)

12 September 2017

title

Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma (English)

1 reference

12 September 2017

1 reference

12 September 2017

L V Ly

1 reference

12 September 2017

K Lodder

1 reference

12 September 2017

M Verlaan-de Vries

1 reference

12 September 2017

A F A S Teunisse

1 reference

12 September 2017

M J Jager

1 reference

12 September 2017

A G Jochemsen

1 reference

12 September 2017

language of work or name

English

0 references

publication date

18 July 2011

1 reference

12 September 2017

1 reference

12 September 2017

1 reference

12 September 2017

1 reference

12 September 2017

page(s)

1105-1116

1 reference

Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.309

Effectiveness of treatments for metastatic uveal melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.309

MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.309

Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.309

The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.309

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.309

MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.309

Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.309

Establishment and characterization of an uveal-melanoma cell line.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.309

MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.309

MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.309

Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.309

DNA damage is a prerequisite for p53-mediated proteasomal degradation of HIF-1alpha in hypoxic cells and downregulation of the hypoxia marker carbonic anhydrase IX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.309

Requirement of ATM for rapid p53 phosphorylation at Ser46 without Ser/Thr-Gln sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.309

Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.309

NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.309

Role of Mdm4 in drug sensitivity of breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.309

Nutlin3 blocks vascular endothelial growth factor induction by preventing the interaction between hypoxia inducible factor 1alpha and Hdm2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.309

Inactivation of the p53 pathway in retinoblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.309

Nutlin-3, an Hdm2 antagonist, inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated inactivation of HIF-1alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.309

The ATM inhibitor KU-55933 suppresses cell proliferation and induces apoptosis by blocking Akt in cancer cells with overactivated Akt.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.309

In aged mice, outgrowth of intraocular melanoma depends on proangiogenic M2-type macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.309

Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.309

HIPK2 regulation by MDM2 determines tumor cell response to the p53-reactivating drugs nutlin-3 and RITA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.309

RITA Inhibits Multiple Myeloma Cell Growth through Induction of p53-Mediated Caspase-Dependent Apoptosis and Synergistically Enhances Nutlin-Induced Cytotoxic Responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.309

ATM mediates phosphorylation at multiple p53 sites, including Ser(46), in response to ionizing radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.309

Topotecan triggers apoptosis in p53-deficient cells by forcing degradation of XIAP and survivin thereby activating caspase-3-mediated Bid cleavage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.309

MDM2 inhibitors for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.309

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.309

Hdmx modulates the outcome of p53 activation in human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.309

Irreversible chromosome damage accumulates rapidly in the absence of ATM kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.309

The influence of cell context on the selection pressure for p53 mutation in human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.309

Small-molecule activation of p53 blocks hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in vivo and leads to tumor cell apoptosis in normoxia and hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.309

Levels of HdmX Expression Dictate the Sensitivity of Normal and Transformed Cells to Nutlin-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.309

Metastatic uveal melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.309

31 March 2020

Identifiers

DOI

10.1038/ONC.2011.309

1 reference

12 September 2017

1 reference